Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Diabet Med ; 1(3): 219-21, 1984 Sep.
Article in English | MEDLINE | ID: mdl-6242801

ABSTRACT

A single dose crossover study in 10 fasting, non-diabetic men compared the 24-hour profiles of blood glucose, plasma insulin, and C-peptide following a single subcutaneous injection of either human insulin zinc suspension crystalline (recombinant DNA), or highly purified porcine insulin zinc suspension (mixed), in a standard dose of 0.2 U/kg. Both insulins produced moderate hypoglycaemia within 3 hours which persisted for 24 hours after administration. The rate of fall of blood glucose was similar from 0-3 hours but was significantly lower after the porcine insulin at 4 and 7 hours (p less than 0.05). Mean plasma insulin values were higher after porcine insulin between 2 and 6 hours (p less than 0.05) and a biphasic pattern was observed following injection of both insulins. Plasma C-peptide declined after each insulin was administered, and was significantly lower between 2 and 7 hours after porcine insulin. The duration of the hypoglycaemic action of human crystalline insulin (recombinant DNA), assessed by blood glucose measurements and C-peptide suppression, was equivalent to porcine insulin zinc suspension (mixed) (Monotard MC, Novo) over 24 hours.


Subject(s)
Insulin, Long-Acting/metabolism , Recombinant Proteins/metabolism , Adult , Animals , Blood Glucose/analysis , C-Peptide/blood , DNA, Recombinant/metabolism , DNA, Recombinant/therapeutic use , Humans , Insulin/blood , Insulin, Long-Acting/therapeutic use , Kinetics , Male , Recombinant Proteins/therapeutic use , Research Design , Swine
2.
Lancet ; 2(8294): 354-7, 1982 Aug 14.
Article in English | MEDLINE | ID: mdl-6124760

ABSTRACT

94 diabetic patients established on treatment with porcine (n = 47) or bovine (n = 47) insulin took part in a double-blind crossover trial, in which 6-week periods of treatment with the appropriate animal insulin were compared with periods of treatment with biosynthetic human insulin (BHI). 6 patients withdrew during the trial, in 3 cases because of hypoglycaemia while taking BHI. In bovine-insulin-treated patients, the mean glucose level (mean of seven capillary-blood samples over 1 day), the modified M index, and total daily insulin requirement were the same on BHI and bovine-insulin treatment. For porcine-insulin-treated patients, mean glucose level and the modified M index were slightly higher on BHI than on porcine-insulin treatment (9.7 vs 9.0 mmol/l and 79.6 vs 65.0, respectively), despite an average increase of 2.3 units/day of BHI after 6 weeks of such treatment. Hypoglycaemic episodes were not significantly more or less frequent on BHI in either group of patients. In both groups fasting blood glucose was higher during BHI treatment than during animal-insulin treatment (14.2 vs 12.8 mmol/l [bovine group]; 12.1 vs 9.6 mmol/l [porcine group]). In bovine-insulin-treated patients blood glucose before the evening insulin injection was higher on BHI than on bovine insulin (11.6 vs 10.0 mmol/l). BHI appears to be a safe alternative to porcine or bovine insulin. Differences in the pharmacokinetics of BHI may account for the observed differences in blood-glucose responses.


Subject(s)
Diabetes Mellitus/drug therapy , Insulin/therapeutic use , Adult , Animals , Blood Glucose/analysis , Cattle , Clinical Trials as Topic , DNA, Recombinant , Double-Blind Method , Humans , Hypoglycemia/diagnosis , Insulin/chemical synthesis , Insulin/metabolism , Kinetics , Middle Aged , Random Allocation , Swine
SELECTION OF CITATIONS
SEARCH DETAIL
...